A first in class small molecule as a novel YB1 inhibitor.

Case ID:
Web Published:


The development of resistance to chemotherapy treatment in solid tumors is associated with up-regulation of the DNA/RNA binding protein Y box binding protein 1 (YB-1) and a worsened prognosis for cancer patients. Oregon Health & Science University researchers have developed a first-in-class small molecule inhibitor of YB-1 that synergizes with chemotherapy to reduce ovarian cancer progression and potentially patient mortality.

Technology Overview

Ovarian cancer has a high mortality rate, with frequent development of treatment resistance and disease relapse. YB-1 has a well-established role in cancer, increasing the stability of many oncogenic transcripts which are associated with disease progression and treatment resistance, and elevated YB-1 expression is associated with shorter term survival in ovarian cancer patients. The laboratory of Dr. Sanjay Malhotra has developed a novel inhibitor of YB-1 with validated efficacy in ovarian cancer models and the potential to improve outcomes in a broad range of cancers that demonstrate treatment resistance.

Beneficial properties of this novel small molecule YB-1 inhibitor include:

•       Potent YB-1 inhibition at low micromolar concentrations in vitro

•       Mediates cell cycle arrest and significantly decreases proliferation and migration of ovarian cancer cells in vitro

•       In vivo efficacy in halting ovarian cancer progression and metastasis in mouse models

•       Ability to synergize with chemotherapy and radiation treatment in ovarian and head and neck cancer models

•       Favorable toxicity profile, with an absence of signs of weight loss, neurotoxicity, or changes in liver enzymes


Tailor D. et al. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chemical Biology 2021. Link

Licensing Opportunity

This technology is available for licensing.



Patent Information:
For Information, Contact:
Anne Carlson
Assoc Dir, Tech Dev & Licensing
Oregon Health & Science University
Sanjay Malhotra
Dhanir Tailor
Therapeutics - Cancer
© 2023. All Rights Reserved. Powered by Inteum